SPYRE THERAPEUTICS, INC. Increase (Decrease) in Other Accounts Payable
SPYRE THERAPEUTICS, INC. (SYRE) reported Increase (Decrease) in Other Accounts Payable of $32.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherAccountsPayable · last filed 2026-08-04
- SPYRE THERAPEUTICS, INC. increase (decrease) in other accounts payable for the quarter ending 2026-06-30 was -$4.00K.
- SPYRE THERAPEUTICS, INC. increase (decrease) in other accounts payable for the quarter ending 2026-03-31 was $36.00K, a 98.15% decline year-over-year.
- SPYRE THERAPEUTICS, INC. increase (decrease) in other accounts payable for the quarter ending 2025-12-31 was -$3.96M.
- SPYRE THERAPEUTICS, INC. increase (decrease) in other accounts payable for the quarter ending 2025-09-30 was $3.94M.
- SPYRE THERAPEUTICS, INC. increase (decrease) in other accounts payable for fiscal 2025 was -$589.00K.
- SPYRE THERAPEUTICS, INC. increase (decrease) in other accounts payable for fiscal 2024 was -$15.98M.
- SPYRE THERAPEUTICS, INC. increase (decrease) in other accounts payable for fiscal 2023 was -$2.40M.
- SPYRE THERAPEUTICS, INC. increase (decrease) in other accounts payable for fiscal 2022 was $0.00.
| Period end | Increase (Decrease) in Other Accounts Payable 3 month | Increase (Decrease) in Other Accounts Payable 6 month | Increase (Decrease) in Other Accounts Payable 9 month | Increase (Decrease) in Other Accounts Payable 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$4.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $32.00K 10-Q · filed 2026-08-04 | -$3.92M derived: sum of 3 quarters · filed 2026-08-04 | $15.00K derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $36.00K 10-Q · filed 2026-05-05 | -$3.92M derived: sum of 2 quarters · filed 2026-05-05 | $19.00K derived: sum of 3 quarters · filed 2026-05-05 | -$2.50M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | -$3.96M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | -$17.00K derived: sum of 2 quarters · filed 2026-02-19 | -$2.53M derived: sum of 3 quarters · filed 2026-08-04 | -$589.00K 10-K · filed 2026-02-19 |
| 2025-09-30 | $3.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $1.42M derived: sum of 2 quarters · filed 2026-08-04 | $3.37M 10-Q · filed 2025-11-04 | $2.52M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | -$2.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | -$572.00K 10-Q · filed 2026-08-04 | -$1.42M derived: sum of 3 quarters · filed 2026-08-04 | -$3.65M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $1.95M 10-Q · filed 2026-05-05 | $1.10M derived: sum of 2 quarters · filed 2026-05-05 | -$1.13M derived: sum of 3 quarters · filed 2026-05-05 | -$7.53M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | -$843.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | -$3.08M derived: sum of 2 quarters · filed 2026-02-19 | -$9.47M derived: sum of 3 quarters · filed 2026-02-19 | -$15.98M 10-K · filed 2026-02-19 |
| 2024-09-30 | -$2.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$8.63M derived: sum of 2 quarters · filed 2025-11-04 | -$15.14M 10-Q · filed 2025-11-04 | -$15.43M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-06-30 | -$6.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | -$12.91M 10-Q · filed 2025-08-05 | -$13.19M derived: sum of 3 quarters · filed 2026-02-19 | -$16.55M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-03-31 | -$6.51M 10-Q · filed 2025-05-08 | -$6.79M derived: sum of 2 quarters · filed 2026-02-19 | -$10.16M derived: sum of 3 quarters · filed 2026-02-19 | -$8.91M derived: sum of 4 quarters · filed 2026-02-19 |
| 2023-12-31 | -$287.00K derived: 10-K 12 month − 10-Q/A 9 month · filed 2026-02-19 | -$3.65M derived: sum of 2 quarters · filed 2026-02-19 | -$2.40M derived: sum of 3 quarters · filed 2026-02-19 | -$2.40M 10-K · filed 2026-02-19 |
| 2023-09-30 | -$3.36M derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2024-11-18 | -$2.12M derived: sum of 2 quarters · filed 2024-11-18 | -$2.12M 10-Q/A · filed 2024-11-18 | -$2.12M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $1.25M derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2024-11-18 | $1.25M 10-Q/A · filed 2024-11-18 | $1.25M derived: sum of 3 quarters · filed 2025-02-27 | |
| 2023-03-31 | $0.00 10-Q/A · filed 2024-11-18 | $0.00 derived: sum of 2 quarters · filed 2025-02-27 | ||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $0.00 10-K · filed 2025-02-27 | ||
| 2022-09-30 | $0.00 10-Q · filed 2023-11-09 | |||
| 2021-12-31 | $0.00 10-K/A · filed 2024-11-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |